Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical research study is to learn if the addition of OSI-906 to cetuximab can improve response. The safety of these drugs will also be studied.

Objectives:

Primary Objective(s): To assess progression-free survival (PFS) among patients with head and neck squamous cell carcinoma (HNSCC) treated with a combination of cetuximab plus OSI-906 and compare it with PFS among patients treated with cetuximab plus placebo.

Secondary Objective(s):

• To assess the safety and toxicity of these treatment regimens.

• To assess the efficacy of these two treatment regimens in terms of overall survival, response rate, and disease control rate

• To assess the efficacy of single agent OSI-906 following cetuximab treatment in terms of response rate and disease control rate in patients who cross-over from Arm B to receive single-agent OSI-906

• To explore blood-based and tissue biomarkers

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: OSI Pharmaceuticals
• Treatments: Cetuximab

Criteria

Inclusion Criteria:

1. Patients must have histologically or cytologically confirmed recurrent or metastatic head and neck squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx.

2. Patients must be willing to have a biopsy of tumor tissue for biomarker analysis.

3. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >/= 20 mm with conventional techniques or as >/= 10 mm with spiral computed tomography (CT) scan or magnetic resonance imaging (MRI). Measurable lymph nodes are required to be >/= 15 mm in size (short axis diameter). Measurable disease in previously radiated areas is acceptable as long as there has been documented progression.

4. Patients must have disease progression: 1) After platinum-based chemotherapy for recurrent/metastatic disease OR 2) Within 6 months of receiving definitive platinum-based combined modality therapy.

5. Previous treatment with cetuximab is allowed, as long as there has been a period >/= 6 months between the last cetuximab treatment and randomization

6. All prior cytotoxic therapy must have been completed at least three weeks prior to treatment on study.

7. Age >/= 18 years

8. ECOG performance status/= 60%

9. Patients must have normal liver function as defined below: total bilirubininstitutional upper limit of normal and aspartate aminotransferase (AST or SGOT)/alanine aminotransferase (ALT or SGPT)normal.

10. Patients - both males and females - with reproductive potential (ie, menopausal for less than 1 year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration.

11. Patients must provide verbal and written informed consent to participate in this study

12. Prior radiation treatment is acceptable as long as it has been completed one week prior to treatment on protocol.

Exclusion Criteria:

1. Patients may not be receiving any other investigational agents with anti-cancer activity.

2. Patients with known, untreated brain metastases. Patients with treated (irradiated or resected) brain metastases are eligible if treatment was completed >/= 28 days prior to study entry and if clinical neurologic function is stable.

3. History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to OSI-906 or other agents used in the study.

4. QTc interval > 450 msec at baseline.

5. Concomitant drugs with a generally accepted risk of causing Torsades de Pointes

6. Congestive heart failure, New York Heart Association (NYHA) Class III or IV

7. History of arrhythmia which is symptomatic and requires treatment, or asymptomatic sustained ventricular tachycardia. Patients with atrial fibrillation controlled on medication are not excluded.

8. Fasting blood sugar > 150 mg/dl at baseline

9. Serious underlying medical condition which would impair the ability of the patient to receive protocol treatment, in the opinion of the treating physician.

10. Pregnant or breast-feeding females.